NASDAQ$LXRX
Lexicon Pharmaceuticals Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Lexicon Pharmaceuticals reported financial results for Q4 2021 and provided an update on key milestones.
Lexicon Pharmaceuticals reported negligible revenues for the fourth quarter. R&D expenses increased, while SG&A expenses also increased. The net loss for the quarter was $25.6 million, or $0.17 per share. As of December 31, 2021, Lexicon had $86.7 million in cash and investments.
- Voluntarily withdrew the sotagliflozin NDA to correct a technical issue and plan to promptly resubmit early in the second quarter of 2022.
- Completing and announcing top-line results in the coming months from our two proof-of-concept Phase 2 studies of LX9211 in diabetic peripheral neuropathic pain and post-herpetic neuralgia.
- R&D expenses for the fourth quarter of 2021 increased to $16.5 million from $1.0 million for the corresponding period in 2020.
- SG&A expenses for the fourth quarter of 2021 increased to $8.8 million from $6.4 million for the corresponding period in 2020, primarily due to higher legal fees during the quarter.
Headline financials
Revenue & EPS history
Lexicon Pharmaceuticals · Revenue · Quarterly
$14K
Revenue by segment
Lexicon Pharmaceuticals · $162K total across 2 segments · Q3 2023
- Net Product Revenue$148K—91.4%
- Royalties and Other$14K—8.6%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+0.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
-0.4%
Avg return
30 days after
56%
36 / 64 earnings
Positive
+30.6%
Q3 2015
Best reaction
-26.0%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.4% | +50.0% | +19.4% | |
| Q4 2025 | -0.6% | +1.8% | -2.5% | |
| Q3 2025 | +3.0% | +13.0% | +1.4% | |
| Q1 2025 | +3.1% | +22.2% | +24.1% | |
| Q4 2024 | +6.6% | +2.7% | +13.5% | |
| Q3 2024 | -14.2% | -22.8% | -35.4% | |
| Q2 2024 | -24.4% | -27.1% | -23.1% | |
| Q1 2024 | +5.5% | +7.3% | +3.0% | |
| Q4 2023 | +16.1% | +19.8% | -6.9% | |
| Q3 2023 | -17.2% | -14.4% | +0.0% | |
| Q2 2023 | -1.1% | -3.7% | -10.6% | |
| Q1 2023 | +12.3% | +43.0% | +11.1% | |
| Q4 2022 | +21.8% | +17.3% | +10.5% | |
| Q3 2022 | +8.7% | +13.1% | -1.0% | |
| Q2 2022 | +13.5% | +19.4% | +16.5% | |
| Q1 2022 | -7.2% | -9.8% | -6.7% | |
| Q4 2021 | -26.0% | -25.3% | -26.3% | |
| Q3 2021 | -11.2% | -9.8% | -25.5% | |
| Q2 2021 | +2.0% | -4.7% | +28.8% | |
| Q1 2021 | -0.4% | -3.7% | -3.5% | |
| Q4 2020 | -1.4% | -2.6% | -23.8% | |
| Q3 2020 | -9.0% | -9.8% | +32.8% | |
| Q2 2020 | +11.5% | +12.6% | +0.0% | |
| Q1 2020 | +3.4% | -7.3% | -1.0% | |
| Q4 2019 | -10.6% | +3.5% | -17.2% | |
| Q3 2019 | -8.6% | -8.8% | +26.5% | |
| Q2 2019 | -21.1% | -19.9% | -20.5% | |
| Q1 2019 | +4.7% | +20.9% | -7.2% | |
| Q4 2018 | +2.2% | +6.3% | -15.3% | |
| Q3 2018 | +8.4% | +8.8% | +3.4% | |
| Q2 2018 | -3.0% | -11.8% | -6.2% | |
| Q1 2018 | +8.4% | +17.3% | +52.2% | |
| Q4 2017 | +1.3% | +4.5% | -1.3% | |
| Q3 2017 | -6.3% | +0.8% | +8.4% | |
| Q2 2017 | -4.4% | -3.7% | -7.1% | |
| Q1 2017 | +2.4% | +2.2% | -9.5% | |
| Q4 2016 | +9.0% | +11.0% | -4.8% | |
| Q3 2016 | -4.2% | -3.0% | -1.3% | |
| Q2 2016 | +1.6% | +0.6% | -11.8% | |
| Q1 2016 | -15.6% | — | — | |
| Q4 2015 | +24.4% | — | — | |
| Q3 2015 | +30.6% | — | — | |
| Q2 2015 | -8.6% | — | — | |
| Q1 2015 | -5.7% | — | — | |
| Q4 2014 | +14.3% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | -6.6% | — | — | |
| Q1 2014 | +1.4% | — | — | |
| Q4 2013 | +3.8% | — | — | |
| Q3 2013 | -2.6% | — | — | |
| Q2 2013 | +7.8% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +1.9% | — | — | |
| Q3 2012 | -9.6% | — | — | |
| Q2 2012 | +3.7% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q4 2011 | +5.6% | — | — | |
| Q3 2011 | -9.9% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +1.9% | — | — | |
| Q4 2010 | +6.3% | — | — | |
| Q3 2010 | -3.7% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2010 | +8.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro